A citation-based method for searching scientific literature

Mikhail Kosiborod, Matthew A Cavender, Alex Z Fu, John P Wilding, Kamlesh Khunti, Reinhard W Holl, Anna Norhammar, Kåre I Birkeland, Marit Eika Jørgensen, Marcus Thuresson, Niki Arya, Johan Bodegård, Niklas Hammar, Peter Fenici. Circulation 2017
Times Cited: 315



Karin Rådholm, Gemma Figtree, Vlado Perkovic, Scott D Solomon, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Terrance D Barrett, Wayne Shaw, Mehul Desai, David R Matthews, Bruce Neal. Circulation 2018
Times Cited: 132




List of shared articles



Times cited


Dapagliflozin and cardiovascular outcomes in patients with Type 2 diabetes.
Dalal Y Al-Bazz, John Ph Wilding. Future Cardiol 2020
0


Cardiovascular Safety and Benefits of Noninsulin Antihyperglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus: Part 2.
Srikanth Yandrapalli, Aaqib Malik, Adam Horblitt, Gayatri Pemmasani, Wilbert S Aronow, William H Frishman. Cardiol Rev 2020
2


Reappraisal on pharmacological and mechanical treatments of heart failure.
Bo Liang, Yu-Xiu Zhao, Xiao-Xiao Zhang, Hui-Ling Liao, Ning Gu. Cardiovasc Diabetol 2020
2


The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study.
Hung-Yi Chen, Jing-Yang Huang, Wun-Zhih Siao, Gwo-Ping Jong. Cardiovasc Diabetol 2020
4

2020 Consensus of Taiwan Society of Cardiology on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases.
Chern-En Chiang, Kwo-Chang Ueng, Ting-Hsing Chao, Tsung-Hsien Lin, Yih-Jer Wu, Kang-Ling Wang, Shih-Hsien Sung, Hung-I Yeh, Yi-Heng Li, Ping-Yen Liu,[...]. J Chin Med Assoc 2020
0

Assessing the cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus: A comprehensive economic evaluation using clinical trial and real-world evidence.
Phil McEwan, Hayley Bennett, Kamlesh Khunti, John Wilding, Christopher Edmonds, Marcus Thuresson, Eric Wittbrodt, Peter Fenici, Mikhail Kosiborod. Diabetes Obes Metab 2020
0


Sodium glucose cotransporter 2 inhibitors: mechanisms of action in heart failure.
Mieczysław Dutka, Rafał Bobiński, Izabela Ulman-Włodarz, Maciej Hajduga, Jan Bujok, Celina Pająk, Michał Ćwiertnia. Heart Fail Rev 2020
0

Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: A nationwide observational study.
Anna Norhammar, Johan Bodegård, Thomas Nyström, Marcus Thuresson, David Nathanson, Jan W Eriksson. Diabetes Obes Metab 2019
22

SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA.
Pantelis Sarafidis, Charles J Ferro, Enrique Morales, Alberto Ortiz, Jolanta Malyszko, Radovan Hojs, Khaled Khazim, Robert Ekart, Jose Valdivielso, Denis Fouque,[...]. Nephrol Dial Transplant 2019
41